XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.2
DISCONTINUED OPERATIONS (Tables)
 6 Months Ended
Jun. 30, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Discontinued Operations The results of operations from discontinued operations during the three and six months ended June 30, 2024, have been reflected as loss from discontinued operations, net of income taxes in the condensed consolidated statements of operations and comprehensive loss and consisted of the following:
Three Months Ended
June 30,		Six Months Ended
June 30,
(In thousands)20242024
Major line items constituting pretax income of discontinued operations
Revenues:
Total revenues$21,762 $29,252 
Operating expenses:
Cost of product revenue7,467 9,030 
Research and development4,440 10,114 
Selling, general and administrative5,055 7,457 
Total operating expenses16,962 26,601 
Income from operations4,800 2,651 
Other expense, net:
Loss on disposal of discontinued operations(1,799)(1,799)
Total other expense, net(1,799)(1,799)
Income from discontinued operations before income tax expense3,001 852 
Income tax expense— — 
Income from discontinued operations, net of income taxes$3,001 $852 
Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition
The following table presents collaboration revenue under the Janssen Collaboration Agreement for the three and six months ended June 30, 2024 (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
20242024
Revenue from Janssen Collaboration Agreement:
Over Time:
Research and Development Services$302 $1,273 
Clinical Supply Services— 2 
Total Revenue from Janssen Collaboration Agreement$302 $1,275 
The following table presents collaboration and product revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition, for the three and six months ended June 30, 2024 (in thousands):
Three Months Ended
June 30, 2024		Six Months Ended
June 30, 2024
MundipharmaMelintaMundipharmaMelinta
Revenue from Collaboration, License and Purchase Agreements:
Point in Time:
Rezafungin Assets, including Sale of Intellectual Property and Inventory$20,833 $— $20,833 $— 
License of Intellectual Property - upon milestone achieved$— $— $813 $— 
Product Revenue— — 2,826 — 
Royalty Revenue11 49 37 125 
Over Time:
Research and Development Services629 140 3,895 457 
Clinical Supply Services9 — 175 — 
Transition Services91 — 91 — 
Total Revenue from Collaboration, License and Purchase Agreements$21,573 $189 $28,670 $582